364 related articles for article (PubMed ID: 25788687)
1. Imbalanced mechanistic target of rapamycin C1 and C2 activity in the cerebellum of Angelman syndrome mice impairs motor function.
Sun J; Liu Y; Moreno S; Baudry M; Bi X
J Neurosci; 2015 Mar; 35(11):4706-18. PubMed ID: 25788687
[TBL] [Abstract][Full Text] [Related]
2. mTORC1-S6K1 inhibition or mTORC2 activation improves hippocampal synaptic plasticity and learning in Angelman syndrome mice.
Sun J; Liu Y; Tran J; O'Neal P; Baudry M; Bi X
Cell Mol Life Sci; 2016 Nov; 73(22):4303-4314. PubMed ID: 27173058
[TBL] [Abstract][Full Text] [Related]
3. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.
Julien LA; Carriere A; Moreau J; Roux PP
Mol Cell Biol; 2010 Feb; 30(4):908-21. PubMed ID: 19995915
[TBL] [Abstract][Full Text] [Related]
4. Yin-and-Yang of mTORC1/C2 in Angelman syndrome mice.
Bi X; Sun J; Baudry M
Oncotarget; 2015 Jun; 6(16):13844-5. PubMed ID: 26116835
[No Abstract] [Full Text] [Related]
5. Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2.
Luo Y; Liu L; Wu Y; Singh K; Su B; Zhang N; Liu X; Shen Y; Huang S
Oncotarget; 2015 Feb; 6(6):4286-98. PubMed ID: 25738366
[TBL] [Abstract][Full Text] [Related]
6. mTORC1 and mTORC2 have largely distinct functions in Purkinje cells.
Angliker N; Burri M; Zaichuk M; Fritschy JM; Rüegg MA
Eur J Neurosci; 2015 Oct; 42(8):2595-612. PubMed ID: 26296489
[TBL] [Abstract][Full Text] [Related]
7. 17ß-Estradiol regulates mTORC2 sensitivity to rapamycin in adaptive cardiac remodeling.
Kusch A; Schmidt M; Gürgen D; Postpieszala D; Catar R; Hegner B; Davidson MM; Mahmoodzadeh S; Dragun D
PLoS One; 2015; 10(4):e0123385. PubMed ID: 25880554
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation.
Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN
J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732
[TBL] [Abstract][Full Text] [Related]
9. Reciprocal regulation of mTOR complexes in pancreatic islets from humans with type 2 diabetes.
Yuan T; Rafizadeh S; Gorrepati KD; Lupse B; Oberholzer J; Maedler K; Ardestani A
Diabetologia; 2017 Apr; 60(4):668-678. PubMed ID: 28004151
[TBL] [Abstract][Full Text] [Related]
10. Fisetin regulates obesity by targeting mTORC1 signaling.
Jung CH; Kim H; Ahn J; Jeon TI; Lee DH; Ha TY
J Nutr Biochem; 2013 Aug; 24(8):1547-54. PubMed ID: 23517912
[TBL] [Abstract][Full Text] [Related]
11. Activation of AMPK/TSC2/PLD by alcohol regulates mTORC1 and mTORC2 assembly in C2C12 myocytes.
Hong-Brown LQ; Brown CR; Navaratnarajah M; Lang CH
Alcohol Clin Exp Res; 2013 Nov; 37(11):1849-61. PubMed ID: 23895284
[TBL] [Abstract][Full Text] [Related]
12. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).
García-Martínez JM; Alessi DR
Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875
[TBL] [Abstract][Full Text] [Related]
13. mTOR has a developmental stage-specific role in mitochondrial fitness independent of conventional mTORC1 and mTORC2 and the kinase activity.
Kalim KW; Zhang S; Chen X; Li Y; Yang JQ; Zheng Y; Guo F
PLoS One; 2017; 12(8):e0183266. PubMed ID: 28813526
[TBL] [Abstract][Full Text] [Related]
14. Regulation of endothelial cell proliferation and vascular assembly through distinct mTORC2 signaling pathways.
Wang S; Amato KR; Song W; Youngblood V; Lee K; Boothby M; Brantley-Sieders DM; Chen J
Mol Cell Biol; 2015 Apr; 35(7):1299-313. PubMed ID: 25582201
[TBL] [Abstract][Full Text] [Related]
15. Deletion of Rictor in neural progenitor cells reveals contributions of mTORC2 signaling to tuberous sclerosis complex.
Carson RP; Fu C; Winzenburger P; Ess KC
Hum Mol Genet; 2013 Jan; 22(1):140-52. PubMed ID: 23049074
[TBL] [Abstract][Full Text] [Related]
16. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
17. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications.
Montero JC; Chen X; Ocaña A; Pandiella A
Mol Cancer Ther; 2012 Jun; 11(6):1342-52. PubMed ID: 22496482
[TBL] [Abstract][Full Text] [Related]
18. A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation.
Dalle Pezze P; Sonntag AG; Thien A; Prentzell MT; Gödel M; Fischer S; Neumann-Haefelin E; Huber TB; Baumeister R; Shanley DP; Thedieck K
Sci Signal; 2012 Mar; 5(217):ra25. PubMed ID: 22457331
[TBL] [Abstract][Full Text] [Related]
19. Fetal brain mTOR signaling activation in tuberous sclerosis complex.
Tsai V; Parker WE; Orlova KA; Baybis M; Chi AW; Berg BD; Birnbaum JF; Estevez J; Okochi K; Sarnat HB; Flores-Sarnat L; Aronica E; Crino PB
Cereb Cortex; 2014 Feb; 24(2):315-27. PubMed ID: 23081885
[TBL] [Abstract][Full Text] [Related]
20. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
